Chemically sterilizing mosquitoes to prevent malaria transmission

Open Access
DOI: 10.18258/1622
$650
Raised
108%
Funded on 12/31/13
Successfully Funded
  • $650
    pledged
  • 108%
    funded
  • Funded
    on 12/31/13

About This Project

Malaria is a parasitic disease spread by mosquitoes. Thus, controlling mosquitoes is the key to controlling malaria. Conventional approaches to vector-control rely on broad-spectrum insecticides, but they are losing their efficacy as mosquitoes develop resistance. This project aims to develop male-specific chemosterilants for the principal malaria mosquito in Sub-Saharan Africa, Anopheles gambiae. Our goal is to apply the “Sterile Insect Technique" (SIT) to A. gambiae by releasing sterilized males to compete with wild mosquitoes for mates, thereby reducing mosquito populations without the use of insecticides

Ask the Scientists

Join The Discussion 〉

What is the context of this research?

Our goal is to chemically sterilize the male Anopheles gambiae mosquito to reduce the spread of malaria in Africa. The reason to target the male is that only female mosquitoes bite people, so releasing sterilized males poses no risk of disease. Our current target is a male-specific enzyme called A. gambiae transglutaminase, or AgTG3.

Transglutaminases bond proteins together to form a cross-linked mesh or gel. The A. gambiae male uses AgTG3 to crosslink a protein called Plugin, coagulating his semen into a gooey plug that he pushes into the female. This ‘mating plug’ is required for the female to store his sperm, so chemical inhibitors of AgTG3 should be specific chemosterilants of A. gambiae mosquitoes.

We have already purified AgTG3, developed assays for its activity, and identified several chemical inhibitors. In this project we will synthesize additional inhibitors in order to:

  1. Perform rigorous kinetic assays to measure the potency of our inhibitors.
  2. Perform crystallographic studies to determine the atomic structure of the enzyme bound to our inhibitors.
  3. Alter the inhibitors’ chemical structures to improve their potency and/or pharmacokinetic properties.

What is the significance of this project?

Malaria is the world’s most devastating parasitic disease causing ~1 million deaths per year, mostly children under the age of five in Sub-Saharan Africa. The war against this disease is tough: there is currently no vaccine, malaria parasites are developing resistance to current antimalarial drugs, and insecticides. Therefore, we must develop new tools to continue the fight to control, and eventually to eradicate, malaria.

The Sterile Insect Technique (SIT) has been successfully used to control many insect pests including the cattle screwworm fly, the Mediterranean fruit fly, and the tsetse fly. Yet SIT has never been successfully deployed against malaria. This is largely due to logistical or regulatory barriers to previous methods of sterilization: γ-irradiation and genetic modification.

Chemosterilization was successfully tested in mosquitoes as early as the 1970s, but never implemented due to environmental concerns related to the chemicals involved. If successful, our research has the potential to provide a new class of specific and environmentally friendly chemicals to facilitate the application of SIT in the fight against malaria.

What are the goals of the project?

Your donation will be used directly to employ an experienced research
chemist at an hourly rate to synthesize and test inhibitors of AgTG3. Our funding goal will allow this researcher to scale up synthesis of our best inhibitor specifically on this project.

Your donation will be matched by additional funds to cover the required health benefits and all the material costs required for these experiments. Backers will receive regular updates on the compounds synthesized and their activity as inhibitors of AgTG3.

We are committed to the dissemination of our research to the public: our results will be published in scientific journals adhering to the Open Access model, with acknowledgement of funding from Microryza backers. Should we be successful in determining the atomic structure of AgTG3 in complex with any inhibitors, this data will be deposited in the publicly accessible Protein Databank.

Budget

  • $500Labor costs
  • $100Reagents

This work will be performed by a research chemist under a contracted
hourly rate. Working in partnership with other researchers, the funding goal will allow our chemist to scale-up our pilot synthesis to provide sufficient material for in vitro kinetic assays and to pursue crystallographic studies of the enzyme-inhibitor complex.

Meet the Team

Tapan Kanai
Tapan Kanai
Jacob Marcus
Jacob Marcus
Richard Baxter
Richard Baxter

Background

Hi, my name is Tapan Kanai. I have a Masters Degree in Chemistry from
Utkal University in Bhubaneswar, India and ten years experience in asymmetric synthesis as a Research Scholar at the Department of Organic Chemistry at the Indian Institute of Science (I. I. Sc), Bangalore, India and in materials chemistry at the Naval Materials Research Laboratory (NMRL). I am currently a Research Associate in the Department of Chemistry at Yale University.
Malaria is prevalent in Odisha, a state of India (see here) where I received my education, so I am very excited at the opportunity to use my expertise in developing new tools to control mosquitoes that transmit it.

Press and Media



Check out the press report about our work on Wired.co.uk:
Read our recent publication in the Journal of Biological Chemistry (Open Access, embargoed until February 15, 2014): Le, B.V. et al. (2012) “Characterization of Anopheles gambiae transglutaminase 3 (AgTG3) and its native substrate Plugin.” J. Biol. Chem. 288, 4844-4853. DOI: 10.1074/jbc.M112.435347, PMCID: PMC3576089
Read the original paper reporting AgTG3 and Plugin in PLoS Biology (Open Access): Rogers et al.(2009) "Transglutaminase-Mediated Semen Coagulation Controls Sperm Storage in the Malaria Mosquito." PLoS Biol 7, e1000272. DOI:10.1371/journal....journal.pbio.1000272